Clinical trial · Observational
Terahertz Metamaterials for Tumour Marker Concentration Identification
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PhD Student completed primary study. Awaiting a new student to take over the project for the secondary objective.
Summary
Brief summary (as posted)
The research the investigators plan to undertake involves the use of a metamaterial at terahertz frequencies. Serum samples will be tested using the metamaterial to determine if this method can be used to measure the concentration of tumour markers present in the sample. Patients who have been tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP will be used for both the positive and negative samples.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Tumour | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Terahertz metamaterials | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evidence of detection for any marker
- timeFrame
- 18 months
- description
- Any correlation showing a difference between samples with marker concentrations above and below the standard threshold values used for tests within the NHS.
Secondary outcomes (1)
- measure
- Quantifying the quality of detection per marker
- timeFrame
- 18 months
- description
- Percentage of detectable samples for each specific marker which showed any evidence of detection in outcome 1.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Any patient recommended by their health professional to be tested for any of the tumour markers being studied at County Durham and Darlington NHS Foundation Trust for any reason. Exclusion Criteria: * Patients with known bloodborne pathogens.
References
Publications (0)
Data not yet available